This is a single-center, blinded, placebo-controlled pilot RCT evaluating corticosteroids for
the treatment of Community Acquired Pneumonia (CAP) that will enroll 100 adults hospitalized
with community-acquired pneumonia. The primary goal is to assess the feasibility of proposed
trial procedures for use in a subsequent phase III trial powered on 6-month cognitive outcome
(MOCA-Blind score). Key outcomes are six-month cognitive and functional status, duration and
severity of symptoms, and mortality.